Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD
Go back to Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD| BARNES GROUP, Inc. (NYSE: B) | Delayed: 37.30 +0.57 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.73 | 52 Week High | $44.27 | |||
| Open | $36.62 | 52 Week Low | $30.07 | |||
| Day High | $37.92 | P/E | 28.47 | |||
| Day Low | $36.41 | EPS | $1.31 | |||
| Volume | 3,392,943 | |||||
